The Food and Drug Administration (FDA) last week approved Bristol Myers Squibb’s antipsychotic drug Cobenfy (xanomeline and trospium chloride), the first schizophrenia treatment with an entirely ...

The Food and Drug Administration approved Cobenfy, a twice-a-day medication that is a new kind of treatment for schizophrenia in adults. Steve Belkowitz/Bristol Myers Squibb hide caption ...

N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers ...

Cobenfy, a new drug made by Bristol Myers Squibb and approved by the FDA last week, triggers muscarinic receptors instead of dopamine receptors. It's the first schizophrenia treatment to do so.

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.

More importantly, the drug could deliver huge value to the healthcare system. In 2019, the economic burden of schizophrenia in America was $343 billion.If Cobenfy can reduce even a fraction of ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

The drug, Cobenfy, was approved last year based on data from three randomized studies comparing the drug to placebo. It was the first new mechanism-of-action approved for schizophrenia in decades.

Cobenfy was approved by the Food and Drug Administration in fall 2024 and represents the first novel approach in decades to treating schizophrenia, which affects an estimated 3.7 million American ...

Bristol Myers Squibb’s Cobenfy failed to outdistance a placebo in a Phase 3 test that evaluated the drug as an adjunct to antipsychotics in schizophrenia patients. Last September, the FDA ...

Bristol Myers Squibb Co.’s treatment for schizophrenia failed in a study designed to expand its use, denting the company’s ambitions to turn it into a blockbuster. Cobenfy, already approved to ...